By Jill Drachenberg — BioSpace
July 15, 2024
Halia Therapeutics, NodThera and Gain Therapeutics target neuroinflammatory processes in hopes of modifying the course of Parkinson’s progression.
Preventing or reversing neuroinflammation could be the next clinical frontier in treating Parkinson’s disease, according to recent research and experts familiar with the biology of the phenomenon.
Several biopharmaceutical companies—including NodThera, Halia Therapeutics, Gain Therapeutics and Olatec—are aiming to halt the neuroinflammatory cycle that contributes to Parkinson’s.
Neuroinflammation has also piqued the interest of Alzheimer’s researchers, with companies such as Vigil Neuroscience and Cerevance targeting the TREM2 protein and KCNK13 gene, respectively.
“This is one of the ways the field is moving now,” said Alan Watt, president and chief scientific officer at NodThera. “The anti-inflammatory component—not just in Parkinson’s, but in all of these neurodegenerative diseases—is now getting recognized as a key driver of the progression.”